BioXcel Therapeutics, Inc. Long-Term Debt, Maturity, Remainder of Fiscal Year
BioXcel Therapeutics, Inc. (BTAI) had Long-Term Debt, Maturity, Remainder of Fiscal Year of $20.23 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Commitment and Contingencies
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear · last filed 2026-08-13
- 2026-06-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $20.23M.
- 2026-03-31: Long-Term Debt, Maturity, Remainder of Fiscal Year $16.82M.
- 2025-09-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $0.00.
- 2025-06-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $0.00.
| Period end | Long-Term Debt, Maturity, Remainder of Fiscal Year |
|---|---|
| 2026-06-30 | $20.23M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $16.82M 10-Q · filed 2026-05-15 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-12 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-12 |
| 2023-09-30 | $26.00K 10-Q · filed 2023-11-14 |
| 2023-06-30 | $139.00K 10-Q · filed 2023-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |